Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

NCT02436577 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence
Healthy Japanese Subjects
Pharmacokinetics

Interventions

DRUG: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
DRUG: Ticagrelor OD tablet (90 mg single dose) administered without water
DRUG: Ticagrelor IR tablet (90 mg) administered with 150 mL of water

Sponsor

AstraZeneca